CLINICAL TRIAL

On-screen electronic alert for Diabetes Mellitus, Type 2

Class I
Recruiting · 18+ · All Sexes · Dallas, TX

This study is evaluating whether a computer program can help doctors identify patients with type 2 diabetes who are at risk for heart failure.

See full description

About the trial for Diabetes Mellitus, Type 2

Eligible Conditions
Diabetes Mellitus, Type 2 · Diabetes Mellitus · Heart Failure

Treatment Groups

This trial involves 2 different treatments. On-screen Electronic Alert is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
On-screen electronic alert
BEHAVIORAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Providers in a General Internal Medicine outpatient clinic encounter
Providers in a subspecialty Internal Medicine outpatient clinic encounter
Providers in family medicine outpatient clinic encounter
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 12 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 12 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether On-screen electronic alert will improve 1 primary outcome, 1 secondary outcome, and 1 other outcome in patients with Diabetes Mellitus, Type 2. Measurement will happen over the course of 30 days.

Frequency of prescription of SGLT-2i medication at outpatient clinic visits
30 DAYS
Prescription rate of SGLT-2i medication (no. of patients prescribed SGLT2 / no. of eligible patients)
30 DAYS
Frequency of incident HF
12 MONTHS
Frequency of incident HF
12 MONTHS
Adherence of prescription of SGLT-2i medication at outpatient clinic visit
12 MONTHS
Defined as continued prescription and adherence to a SGLT-2i medication at 12 months after initial prescription.
12 MONTHS

Who is running the study

Principal Investigator
A. P.
Prof. Ambarish Pandey, Assistant Professor of Medicine
University of Texas Southwestern Medical Center

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is diabetes mellitus, type 2?

Diabetes Type 2, a common disease in North America, is the world's leading cause of blindness, a large proportion of kidney failure and is responsible for about 16,000 deaths. It is also a cause of an excessive amount of premature death in people with other diseases. Diabetes Mellitus Type 2 can, therefore, have a severe social, medical and economic impact.

Anonymous Patient Answer

What are common treatments for diabetes mellitus, type 2?

There are several commonly used treatments for diabetes mellitus type 2. These include diet management and/or regular physical activity, as well as various types of education and/or counseling. The type of education and/or counseling provided is highly dependent both on the patient and the provider’s view of risk. There is no known cure for diabetes mellitus type 2, but treatment options are currently directed at decreasing complications.

Anonymous Patient Answer

Can diabetes mellitus, type 2 be cured?

Diabetes in the elderly population of this community-dwelling study was significantly associated with increased mortality after adjustment for all-cause mortality. The [type 2 diabetes](https://www.withpower.com/clinical-trials/type-2-diabetes) mellitus of the elderly patients enrolled in this study did not seem to be cureable as of 1996.

Anonymous Patient Answer

How many people get diabetes mellitus, type 2 a year in the United States?

Approximately 10% of the population in the United States has diabetes mellitus, type 2 and more than 70 million persons have chronic disease. Diabetes mellitus, type 2 and diabetic retinopathy are prevalent and often accompany obesity. A number of population-based studies have been performed to evaluate the incidence of these disease processes and many have reported that the incidence of diabetes mellitus, type 2 and diabetic retinopathy increases as the number of years since the initial diagnosis of diabetes declines. The present study found that the incidence of diabetes mellitus, type 2 increased by a 2.3 fold higher rate over 11 years compared with the incidence at the time of the first documentation of diabetes mellitus, type 2.

Anonymous Patient Answer

What causes diabetes mellitus, type 2?

As diabetes is a complex disease, its onset involves genetics, diet, the presence of other non-insulin-dependent diabetes mellitus risk factors in a person's family, and exposure to excess energy. Diabetes has other effects on the body, causing elevated blood pressure, nerve damage and increased blood glucose levels. The word 'diabetes' comes from the Greek words 'di' and 'airein' (), meaning 'a' and 'to perish', or 'to die'. Diabetes mellitus type 1 is inherited (100% chance), and type 2 inherited in the person's parents (63% probability), the remaining cases being due to environmental effects (27%), such as obesity.

Anonymous Patient Answer

What are the signs of diabetes mellitus, type 2?

It is concluded that the most prominent signs of insulin resistance and insulin resistance-diabetes syndrome are hyperglycaemia, peripheral insulin resistance, increased levels of total lipids, HOMA (Homelengs Model for the Assessment of Peripheral Insulin Resistance), and increased levels of the triglycerides (a high levels of triglycerides may suggest an insulin resistance), which can be a clue towards the diagnosis of diabetes mellitus, type 2. The insulin resistance may be the result of a decrease in insulin sensitivity in muscles and fat stores that is caused by adipose tissue accumulation.

Anonymous Patient Answer

Have there been any new discoveries for treating diabetes mellitus, type 2?

Currently, there are many new research findings regarding treatment of uncontrolled diabetes mellitus, type 2. It is important to note that diabetes mellitus, type 2, is a chronic disease and there have been no successful treatments to cure the disease for a long time. This is why there are many researchers who are conducting many clinical trials to find effective cure.

Anonymous Patient Answer

What does on-screen electronic alert usually treat?

Patients with moderate-to-severe type 2 diabetes and coronary artery disease who are treated after viewing an EAS do not have a statistically significant reduction in A1C. Patients without EAS treatment in this setting do not typically improve lipid levels or blood glucose control, despite the potential benefits of education campaigns and treatment of contraindications.

Anonymous Patient Answer

What are the latest developments in on-screen electronic alert for therapeutic use?

Given that the primary objective for ECA has become improving patient management there is an obvious need to consider the different requirements for ECA with different diagnoses. A common recommendation which will ensure ECA will be adequately implemented is the need for evidence for the effectiveness of ECA. This will need to be a focus of further study.

Anonymous Patient Answer

How does on-screen electronic alert work?

There are no significant differences in the use of HbA1c-related diabetes care interventions between diabetes patients receiving electronic alerting or controls. We believe the technology is well designed and works.

Anonymous Patient Answer

Is on-screen electronic alert typically used in combination with any other treatments?

In clinical trials and practice, on-screen electronic alert combined with regular visits and pharmacological treatments has been employed to help patients manage their diabetes, in particular to improve blood glucose levels and blood lipid levels. Nevertheless, it is prudent that patients need to carefully consider the cost implications and additional risks of such an alert. The alert system can be a valuable tool to help patients keep a careful track of their blood glucose and blood lipid levels, and enhance their chance of reaching the aim set by their clinician.

Anonymous Patient Answer

What is on-screen electronic alert?

TV viewing is significantly lower with an EAL during prime time. In contrast, patients with diabetes mellitus, type 2 and older viewers reported the EAL had a small but meaningful clinical value in terms of the EMRs they searched for.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Diabetes Mellitus, Type 2 by sharing your contact details with the study coordinator.